grant
Design and Synthesis of HIV Integrase as Potential Anti-AIDS Drugs
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY20251H-Purin-6-amineAIDSAIDS VirusAIDS drugsAcetyl CoAAcetyl Coenzyme AAcquired Immune DeficiencyAcquired Immune Deficiency SyndromeAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency SyndromeAcquired Immunodeficiency Syndrome VirusAdenineAffinityAmino AcidsAnti-AIDS AgentsAnti-AIDS DrugsAnti-HIV AgentsAnti-HIV DrugsAnti-Human Immunodeficiency Virus AgentsAssayBindingBioassayBiological AssayBiological FunctionBiological ProcessCOVID crisisCOVID epidemicCOVID pandemicCOVID-19 crisisCOVID-19 epidemicCOVID-19 eraCOVID-19 global health crisisCOVID-19 global pandemicCOVID-19 health crisisCOVID-19 pandemicCOVID-19 periodCOVID-19 public health crisisCOVID-19 yearsCausalityClinicalClinical TrialsCollaborationsComplexCountryCryo-electron MicroscopyCryoelectron MicroscopyDNADNA mutationDeoxyribonucleic AcidDevelopmentDiseaseDisorderDrug resistanceE1A Binding Protein p300EP300EP300 geneEconomic IncomeEconomical IncomeElectron CryomicroscopyEtiologyExhibitsFDA approvedGene TranscriptionGenerationsGenesGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGoalsGrowth AgentsGrowth FactorGrowth SubstancesH-bondHIVHIV IntegraseHIV Integration ProteinHIV-1HIV-IHIV1Histone H3Histone H3.3HistonesHost FactorHost Factor ProteinHuman Immunodeficiency Virus Type 1Human Immunodeficiency VirusesHuman immunodeficiency virus 1Hydrogen BondingIncomeInfectionIntegraseIntegration Host FactorsKAT3BL-LysineLAV-HTLV-IIILaboratoriesLeadLymphadenopathy-Associated VirusLysineMediatingMetalsMicroscopyModificationMolecular InteractionMutationNaphthyridinesNucleosomesPb elementPersonsPositionPositioning AttributeProcessProteinsProteins Growth FactorsRNA ExpressionRecommendationRegimenResistanceResistance profileResistant profileS-acetate Coenzyme ASARS-CoV-2 epidemicSARS-CoV-2 global health crisisSARS-CoV-2 global pandemicSARS-CoV-2 pandemicSARS-coronavirus-2 epidemicSARS-coronavirus-2 pandemicSevere Acute Respiratory Syndrome CoV 2 epidemicSevere Acute Respiratory Syndrome CoV 2 pandemicSevere acute respiratory syndrome coronavirus 2 epidemicSevere acute respiratory syndrome coronavirus 2 pandemicShapesSideStructureTestingTranscriptionTransferaseTransferase GeneTransmissionTrp-ProVariantVariationViralVirus-HIVVitamin B4WorkaminoacidantiAIDS agentcausationchelationcombatcoronavirus disease 2019 crisiscoronavirus disease 2019 epidemiccoronavirus disease 2019 global health crisiscoronavirus disease 2019 global pandemiccoronavirus disease 2019 health crisiscoronavirus disease 2019 pandemiccoronavirus disease 2019 public health crisiscoronavirus disease crisiscoronavirus disease epidemiccoronavirus disease pandemiccoronavirus disease-19 global pandemiccoronavirus disease-19 pandemiccryo-EMcryoEMcryogenic electron microscopydesigndesigningdevelopmentaldisease causationdrug resistantgenome mutationheavy metal Pbheavy metal leadhepatoma-derived growth factorhistone acetyltransferase p300improvedincomesinhibitorinsightinterestlens epithelium-derived growth factormutantnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generationnext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapynucleobasep300resistance mechanismresistance to Drugresistantresistant mechanismresistant to Drugscaffoldscaffoldingsevere acute respiratory syndrome coronavirus 2 global health crisissevere acute respiratory syndrome coronavirus 2 global pandemicsmall moleculetransmission processtryptophyl-prolineviral DNAvirus DNA
Description preview
Goal One: Second-generation INSTIs are strongly recommended for people living with HIV-1 (PLWH). The emergence of resistance to second-generation INSTIs has been infrequent and has not yet been a major issue in high-income countries. However, the delayed rollouts of these INSTIs in low- to middle-income countries during the covid pandemic combined…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click